[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"uveitis-anterior\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:uveitis-anterior":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,75,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100053772","phase-4-adalimumab-dose-adjustment-for-pediatric-uveitis-treatment-trial-100053772",false,"NCT07699107","Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial","ADAPT","Inclusion Criteria:\n\n* Stated willingness to comply with all study procedures and availability for the duration of the study period\n* History of juvenile idiopathic arthritis (JIA) or chronic anterior uveitis (CAU), diagnosed prior to 16 years of age (patient may be older than 16 at time of enrollment)\n* ≥2 years of age (per FDA approval for use in children with polyarticular JIA)\n* Weight must be ≥15kg\n* Formal diagnosis of JIA-associated uveitis or CAU with no other suspected etiology\n* ≥24 consecutive months of controlled ocular inflammation (≤0.5+ anterior chamber cell, ≤0.5+ vitreous haze, and no active retinal\u002Fchoroidal lesions in either eye)\n* ≥24 consecutive months of controlled arthritis verified by a pediatric rheumatologist if defined as JIA-associated uveitis\n* ≥24 consecutive months of treatment with adalimumab or biosimilar of adalimumab\n* ≥180 days on a stable dose of adalimumab or biosimilar of adalimumab; dose must be no greater than 20mg (if weight \\\u003C30kg), or 40mg (if weight ≥30kg), injected every two weeks\n* If on biosimilar of adalimumab, ≥90 days on the biosimilar\n* Ability to continue to obtain commercial supply of adalimumab or biosimilar\n* If on a conventional disease-modifying anti-rheumatic drug (cDMARD) (injectable or oral methotrexate, mycophenolate mofetil, azathioprine, or leflunomide), dose must be ≤25 mg weekly for methotrexate, ≤3 g daily for mycophenolate mofetil, ≤250 mg daily for azathioprine, or ≤20 mg daily for leflunomide; dose and route of administration must be stable for ≥90 days\n* Willingness to limit consumption of alcohol during the study period\n* Agreement to avoid live attenuated vaccinations\n* Agreement to use highly effective contraception or abstinence for ≥28 days prior to screening and throughout the study period (for males and females of reproductive age)\n* Suitable, in the opinion of the Investigator, to continue treatment with adalimumab\u002Fbiosimilar per regional labeling\n\nExclusion Criteria:\n\n* History of acute anterior uveitis characterized by redness and symptoms, including but not limited to floaters, pain, and light sensitivity\n* Intraocular surgery in the past 90 days or planned surgery in the next 24 weeks\n* Severe cataract or opacity preventing view to the posterior pole in both eyes\n* Chronic hypotony (\\\u003C5mmHg for ≥90 days) in either eye\n* Treatment with oral corticosteroids or intraocular corticosteroid injection within the last 24 weeks\n* Use of topical corticosteroid eye drops within the last 90 days\n* Use of nonsteroidal anti-inflammatory drug (NSAID) eye drops within the last 90 days\n* Pregnancy or lactation (a pregnancy test will be conducted at baseline and follow-up visits for females post-menarche)\n* Presence of intraretinal or subretinal fluid in either eye\n* Prior safety or tolerability issues with adalimumab\n* History of cancer, active tuberculosis, or hepatitis B\n* Other medical condition expected to dictate treatment course during the study\n* Any of the following laboratory test results on their most recent tests within the past 90 days prior to screening\u002Fenrollment: leukocyte count \\\u003C2500, platelet count ≤75000, hemoglobin\\\u003C9.0, aspartate transaminase (AST) or alanine transaminase (ALT) ≥ 2 times the upper limit of normal range, creatinine ≥1.5","ALL","2 Years",{"count":19,"type":20},160,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The goal of this clinical trial is to learn whether children and young adults with well-controlled juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior uveitis can safely take adalimumab (or biosimilar) injections less often while maintaining control of their disease.\n\nThe main question it aims to answer is: can adalimumab\u002Fbiosimilar injections be given less frequently without uveitis (eye inflammation) or arthritis (joint inflammation) returning?\n\nResearchers will compare adalimumab\u002Fbiosimilar injection schedules of every 2 weeks, 4 weeks, 8 weeks, and 12 weeks to determine how injection frequency affects disease control.\n\nParticipants will:\n\n* Take adalimumab\u002Fbiosimilar injections every 2, 4, 8, or 12 weeks.\n* Attend study visits every 6 weeks over 24 weeks, with an additional follow-up visit at 48 weeks for checkups, tests, and questionnaires.\n* Keep a diary of how often they take adalimumab\u002Fbiosimilar and other drugs they take for their uveitis\u002Farthritis.",[26,27],"Juvenile Idiopathic Arthritis Associated Uveitis","Uveitis, Anterior",[29,30,31,32],"Adalimumab","JIA-associated uveitis","Chronic anterior uveitis","reduced frequency dosing","NOT_YET_RECRUITING","2026-07-07",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":20},"2026-09",{"date":41,"type":20},"2030-11",{"name":43,"class":44},"Nisha Acharya","OTHER",18,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100476632","phase-3-the-use-of-two-yutiq-versus-sham-for-treatment-of-chronic-non-infectious-intraocular-inflammation-affecting-the-posterior-segment-100476632","NCT05486468","The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment","The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (TYNI Trial)","TYNI","Inclusion Criteria:\n\nGeneral Inclusion Criteria:\n\n1. Male or non-pregnant female in good general health at least 18 years of age, understands the language of the informed consent, and is willing and able to provide written informed consent and sign\u002Fdate a health information release (HIPAA form) before any study procedures are performed.\n2. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.\n\nOcular Inclusion Criteria (Study Eye):\n\n1. Diagnosed with chronic unilateral or bilateral noninfectious posterior segment inflammation (with or without anterior uveitis) that demonstrated a clinical response to ≥1 previous corticosteroid treatment of any localized type (eg, topical steroid 2 to 4 times per day or intra- or peri-ocular injection) or systemic corticosteroid\u002Fimmunosuppressant treatment with recurrence following treatment indicating chronicity according to the Investigator's judgment.\n2. Presence of active posterior segment inflammation as determined by the Investigator.\n3. Vitreous haze grade ≥ 2 based on the standardization of uveitis nomenclature (SUN) criteria.\n4. Less than 10 anterior chamber cells\u002Fhigh power field determined by slit lamp examination.\n5. Not planning to undergo elective ocular surgery during the study.\n\nExclusion Criteria:\n\nGeneral Exclusion Criteria:\n\n1. Subjects with known hypersensitivity to any components of YUTIQ.\n2. Female subjects who are pregnant or breastfeeding.\n3. Has any acute or chronic medical disease or psychiatric condition that, in the opinion of the Investigator, would preclude participation in the study or put the subject at risk due to study treatment or procedures.\n\nOcular Exclusion Criteria (Study Eye):\n\n1. History of anterior uveitis only (without associated uveitis that affected the posterior segment).\n2. Presence of a vitreous hemorrhage.\n3. Uveitis with infectious etiology.\n4. Intraocular inflammation associated with a condition other than non-infectious uveitis (e.g., intraocular lymphoma).\n5. Current infectious diseases of the cornea and conjunctiva, mycobacterial infections of the eye, or fungal diseases of ocular structures.\n6. Subjects with ACIOL (Anterior Chamber Intraocular Lens) or rupture of the posterior lens capsule.\n7. Diagnosis of any form of glaucoma or ocular hypertension at screening, unless the study eye is being treated with ≤2 intraocular pressure (IOP)-lowering medications and\u002For has been previously treated with an incisional surgical procedure resulting in stable IOP in the normal range (10 to 21 mmHg).\n8. Intraocular pressure \\>21 mmHg or concurrent therapy at screening with \\>2 IOP-lowering pharmacologic agents in the study eye.\n9. Any eye surgery within 12 weeks prior to Day 1 of the study.\n10. Subjects who are unable to attend scheduled follow-up visits throughout the 12-month study.\n11. Has a significant media opacity precluding evaluation of retina and vitreous in the study eye.","18 Years",{"count":56,"type":20},30,[58],"PHASE3","The Use of Two YUTIQ versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (TYNI Trial)",[61,62,27,63],"Uveitis","Uveitis, Posterior","Uveitis, Intermediate","RECRUITING","2025-08-06",{"date":67,"type":37},"2025-08-11",{"date":69,"type":37},"2022-10-05",{"date":71,"type":20},"2026-12",{"name":73,"class":44},"Texas Retina Associates",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":83,"enrollmentInfo":84,"targetDuration":86,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":74},"100571447","observational-prospective-turkish-inception-cohort-of-uveitis-and-spondyloarthritis-100571447","NCT06720376","Observational Prospective Turkish Inception Cohort of Uveitis and Spondyloarthritis","Assessment of Spondyloarthritis in an Acute Anterior Uveitis Inception Cohort: a Cross Sectional and Prospective Comparative Study of HLA-B27-positive and -negative Cases","OPTICUS","Inclusion Criteria:\n\n* patients with uveitis\n\nExclusion Criteria:\n\n* patients diagnosed spondyloarthiritis before from the uveitis attack\n* patients with infectious uveitis","75 Years",{"count":85,"type":20},100,"5 Years","OBSERVATIONAL","Spondyloarthritis (SpA) encompasses a group of inflammatory rheumatic diseases characterized by axial and\u002For peripheral arthritis, along with extra-articular manifestations such as enthesitis, dactylitis, uveitis, and skin lesions. Axial spondyloarthritis (axSpA), the hallmark of which is chronic sacroiliitis, can progress to vertebral fusion (\"bamboo spine\") in advanced cases. The prevalence of axSpA varies globally, ranging from 0.1% to 1.4%, with a higher incidence in men and a typical onset in the second or third decades of life. Diagnostic approaches include imaging techniques such as sacroiliac MRI and radiographs, alongside clinical criteria like inflammatory back pain, NSAID responsiveness, peripheral arthritis, and HLA-B27 positivity. Disease management primarily involves NSAIDs, with biologics used for refractory cases, and disease activity is monitored using indices such as BASDAI and ASDAS.\n\nAcute anterior uveitis (AAU) is the most common extra-articular manifestation of SpA, particularly associated with HLA-B27 positivity. It often presents unilaterally with redness, pain, and photophobia but can lead to severe complications if inadequately treated. Around 50% of patients with HLA-B27-positive AAU have underlying SpA, and the prevalence of uveitis increases with longer disease duration. While the link between SpA and AAU is well-established, further research is needed to determine optimal systemic treatment and follow-up protocols. This study aims to assess the prevalence and clinical characteristics of SpA in patients presenting with AAU at ophthalmology clinics.",[90,27],"Spondylarthritis",[92],"Spondylarthritis, Acute Anterior Uveitis, Inflammatory Back Pain, HLA-B27","2024-12-03",{"date":95,"type":37},"2024-12-06",{"date":97,"type":37},"2023-01-15",{"date":99,"type":20},"2030-01-15",{"name":101,"class":44},"Marmara University",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":113,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":74},"100514919","imaging-based-uveitis-screening-for-children-with-juvenile-idiopathic-arthritis-100514919","NCT05984758","Imaging Based Uveitis Screening for Children With Juvenile Idiopathic Arthritis","A Randomised Feasibility Study of Imaging Based Uveitis Screening for Children With Juvenile Idiopathic Arthritis","UVESCREEN1","Inclusion Criteria:\n\n* Patients newly diagnosed (within preceding 12 months) with JIA who are eligible for uveitis surveillance\n* Aged 2-12 years\n\nExclusion Criteria:\n\n* A previous \u002F existing diagnosis of uveitis\n* Any co-existing ocular or neurological abnormality which impacts on current corrected visual function, or could impact on future corrected visual function\n* Developmental\u002Flearning difficulties that preclude concordance with examination \u002F informed assent","12 Years",{"count":112,"type":20},80,[114],"NA","This study seeks to describe, for children undergoing uveitis surveillance following a new diagnosis of juvenile idiopathic arthritis, the feasibility metrics of undertaking a randomised comparative study of routine slit lamp examination (SLE) versus imaging based (anterior segment optical coherence tomography, OCT) surveillance in order to inform the development of a larger multi-centre trial.",[27,117],"Juvenile Idiopathic Arthritis",[119,120,121,122],"Screening","Surveillance","Imaging","Optical coherence tomography","2024-03-11",{"date":125,"type":37},"2024-03-12",{"date":127,"type":20},"2024-05-01",{"date":129,"type":20},"2026-10-01",{"name":131,"class":44},"Institute of Child Health"]